The treatment of ischemic heart disease mainly depends onthe formation of blood vessels and the survival of cardiacmyocytes. This paper will research the enhancement of EPCcells by mesenchymal stem cells in the treatment of ischemicheart disease. Mouse bone marrow was collected, MSCs cellswere isolated and cultured. Flow cytometry was used to testthe expression of CD34 and CD44. Then MSCs cells andendothelial progenitor cells co-culture 48 h, and 24 Wistarrats were randomly divided into EPCs group, EPCs MSCs +group and the control group. MSCs 2×106, EPCs 2×106, EPCs2×106, and PBS buffer were injected into five differentregions around ischemic myocardium. The changes in cardiacfunction were assessed by echocardiography after 4 weeks.MSCs 2×106, EPCs 2×106, EPCs 2×106, and PBS buffer... wereinjected into five different regions around ischemicmyocardium. The changes in cardiac function were assessed byechocardiography after 4 weeks. The rats were sacrificed,and the expression of VEGF was detected byimmunohistochemistry and immunofluorescence. The surfacemarkers CD34 and CD44 of MSCs and EPCs were differentiallyexpressed. We successfully isolated MSCs and EPCs cells.Meanwhile, the proliferation index Ki67 was highlyexpressed, suggesting that MSCs could effectively promotethe proliferation activity of EPCs. Echocardiography showedthat after MSCs+EPCs treatment, the left ventricularejection fraction, end-diastolic volume and cardiac volumeof the rats were significantly improved, with statisticallysignificant differences from the control group and the EPCsgroup (P<0.05), Meanwhile, the expression of VEGF inMSCs+EPCs group was also significantly increased (P<0.05).Mesenchymal stem cells can enhance the therapeutic effect ofEPC cells in ischemic heart disease, which can promotemyocardial angiogenesis, improve ventricular remodeling andcardiac function.